Overview: Multiple Myeloma (MM) is a plasma cell malignancy originating in the bone marrow and is frequently accompanied by severe skeletal complications. Over 80% of MM patients develop osteolytic bone disease, resulting in fractures, pain, and reduced quality of life. Consequently, MM treatment strategies combine anti-cancer therapies with bone-modifying agents designed to limit cancer-induced bone […]